GENMAB
-
Genmab vil stige fremadrettet, der mangler nyheder om Hexabody, ny indkadidat, vil Daratumumab få fast track, milestones ved opstart, godkendelse i Japan med Arzerra. nye lande med Arzerra, herunder milestones, nye Duebody aftaler, samt stigende salg af Arzerra og herunder stigende royalities, samt godkendelse af Arzerra her til sommer, mulige milestone ved Roche med inclamumab, hvis den går videre i fase 3. Lad os håbe at nyhederne begynder at rulle ind snarest. Mit kursmål ved udgangen af året er 180.
-
Det er den tredje headline du laver indenfor en uges tid. Kunne man ikke fortsætte i de tidligere evt eller en anden eksisterende? Det ville give mere plads til andre nyheder en blot Genmab på forsiden.
Ellers ok argumenter.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind